Charlien Berghen
Katholieke Universiteit Leuven
DissectionInternal medicineRadiologyUrologySurgerySeries (stratigraphy)OncologyBiochemical recurrenceAndrogen deprivation therapyMetastasectomyMetastasisProstatectomyProstate cancerLymph nodeRecurrent prostate cancerIn patientPost prostatectomySalvage radiationRadiation therapyTerm (time)Medicine
52Publications
5H-index
59Citations
Publications 59
Newest
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 8 authors...
For patients presenting with limited metastatic disease burden, known as the oligometastatic state of disease, a more aggressive treatment approach targeting the new or progressive metastatic lesions might improve patient outcome, with no or only limited toxicity to be expected from the treatment. This review provides an overview of the existing evidence and on-going trials on oligometastatic disease and metastasis-directed therapy in the field of renal, bladder and prostate cancer.
Source
#1Nicola FossatiH-Index: 44
#2Jeffrey KarnesH-Index: 10
Last. Alberto BrigantiH-Index: 99
view all 25 authors...
Source
#1Elio MazzoneH-Index: 15
#2Nicola FossatiH-Index: 44
Last. Alberto BrigantiH-Index: 99
view all 25 authors...
Source
#1Nicola FossatiH-Index: 44
#2Jeffrey KarnesH-Index: 10
Last. Alberto BrigantiH-Index: 99
view all 25 authors...
Source
#1Giorgio GandagliaH-Index: 55
Last. Alberto BrigantiH-Index: 99
view all 22 authors...
INTRODUCTION AND OBJECTIVE:Curative intent therapies such as radical prostatectomy (RP) might represent an option in prostate cancer (PCa) patients with enlarged lymph nodes at imaging (cN1), no da...
Source
#1Giorgio GandagliaH-Index: 55
#2Axel HeidenreichH-Index: 73
Last. Alberto BrigantiH-Index: 99
view all 21 authors...
INTRODUCTION AND OBJECTIVE:The STAMPEDE trial recently demonstrated a survival benefit for patients with oligometastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) plus p...
Source
#1Antonino Battaglia (UCL: Université catholique de Louvain)H-Index: 8
#2Gaetan Devos (UCL: Université catholique de Louvain)H-Index: 8
Last. S. Joniau (UCL: Université catholique de Louvain)H-Index: 6
view all 16 authors...
The authors have requested the removal of the Excel file in Electronic Supplementary Material to protect patient's privacy.
Source
#1Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 5
Last. G. De Meerleer (Katholieke Universiteit Leuven)H-Index: 9
view all 4 authors...
Abstract For patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (PSA) monitoring and the selected use of SRT has some advantages when compared with adjuvant radiotherapy. The most important one is avoidance of a potential overtreatment of patients who would never have disease progression, even in the pres...
Source
#1Gaëtan Devos (Katholieke Universiteit Leuven)H-Index: 6
#2Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
Last. Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
view all 4 authors...
Source
#1Gaëtan Devos (Katholieke Universiteit Leuven)H-Index: 6
#2Tim Muilwijk (Katholieke Universiteit Leuven)H-Index: 7
Last. Steven Joniau (Katholieke Universiteit Leuven)H-Index: 74
view all 12 authors...
ABSTRACT: Introduction: Salvage lymph node dissection (sLND) has been proposed as a treatment option for prostate cancer patients with lymph node (LN) recurrence following radical prostatectomy to delay or avoid palliative androgen deprivation therapy (ADT). Historically sLND has been performed using an open approach, with its associated morbidity. A limited number of studies have reported peri-operative outcomes following robot-assisted sLND. However, a direct comparison with the open approach ...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.